Status
Conditions
Treatments
About
The goal of this clinical trial is to assess the impact of two 8-week motor-cognitive exercise programs - Cognicise and yoga - on psychological, respiratory, cardiovascular, postural, and biochemical health in elderly women.
The main objectives are to evaluate whether these programs:
Improve psychological parameters such as mood, quality of life, depressive symptoms, and cognitive abilities;
Enhance respiratory function, including lung volumes and ventilation;
Influence cardiovascular parameters such as blood pressure and heart rate;
Improve chest mobility, physical fitness, and cardiorespiratory capacity;
Induce favorable changes in selected blood biomarkers, including neurotrophic factors, hormones, glucose, lipids, and blood morphology;
Improve postural stability, as assessed through posturographic analysis.
The study compares the effects of yoga and Cognicise to a control group that does not receive any intervention.
Participants in the yoga and Cognicise groups will take part in supervised sessions twice a week for 8 weeks (each session lasting 45 minutes).
Participants from all three groups (yoga, Cognicise, and control) will undergo pre- and post-intervention assessments, including:
Psychological questionnaires;
Spirometry and cardiorespiratory tests;
Blood pressure and heart rate measurements;
Chest mobility and physical fitness tests;
Posturographic assessment of postural control during quiet standing with eyes open and closed;
Laboratory blood tests (including BDNF, GDNF, 25(OH)D, TSH, testosterone, cortisol, insulin, glucose, lipid profile, and complete blood count with differential).
The aim is to determine whether structured motor-cognitive training leads to measurable health benefits compared to no intervention.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Women aged over 65 years; Community-dwelling; Score of at least 7 points on the Abbreviated Mental Test Score (AMTS).
Exclusion Criteria (presence of at least one of the following):
Locomotor system disorders preventing independent movement; Morbid obesity; Active or stable cancer (ongoing radiation or chemotherapy); Liver disease with ALT > 3× upper limit of normal; Chronic kidney disease (eGFR < 30 mL/min/1.73 m²); Acute inflammation (CRP > 5 mg/dL); Unstable ischemic heart disease; History of ischemic or hemorrhagic stroke within the last 6 months; History of STEMI with drug-eluting stent implantation; NSTEMI within the past 12 months; Inherited metabolic disorders (e.g., phenylketonuria, galactosemia); Autoimmune diseases (e.g., acute thyroiditis, celiac disease, systemic connective tissue disease, hemolytic anemia, vitiligo, Addison's disease, hyperbilirubinemia); Non-specific enteritis (e.g., Crohn's disease, ulcerative colitis); Psychological disorders; Current antibiotic therapy; Current steroid therapy.
Primary purpose
Allocation
Interventional model
Masking
70 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal